瑞舒伐他汀与阿托伐他汀治疗冠心病患者的降脂疗效对比研究

Comparative Study of Lipid-lowering Efficacy of Rosuvastatin Calcium and Atorvastatin Tablets in the Treatment of Patients with Coronary Heart Disease

目的:对比研究瑞舒伐他汀与阿托伐他汀治疗冠心病的降脂疗效。方法:选取在我院接受治疗的冠心病患者86例,随机分为观察组和对照组各43例。对照组给予阿托伐他汀,观察组给予瑞舒伐他汀,比较两组患者降脂疗效及不良反应情况。结果:两组患者治疗后TC、TG、LDL-C均有明显下降(P<0.05);与对照组相比,观察组TC和LDL-C水平下降更明显(P<0.05);观察组血脂达标率显著高于对照组,差异有统计学意义(P<0.05),且两组患者在治疗期间均未出现严重不良反应。结论:瑞舒伐他汀在降脂和效价比方面比阿托伐他汀更具有优势,且安全、可靠,副作用小,值得在临床上应用和推广。

Objective：To compare lipid-lowering effectiveness of rosuvastatin and atorvastatin in the treatment of coronary heart disease.Methods：The 86 patients were divided into two groups. Control group give atorvastatin, observation group was given rosuvastatin. Results：two groups of patients after treatment TC,TG,LDL-C were significantly decreased （P〈0.05）;Compared with the control, the observation group TC and LDL-C level down more obvious （P〈0.05）;The observation group blood fat success rate is significantly higher than that in control group （P〈0.05）.Conclusion：Rosuvastatin in lipid-lowering and potency ratio than atorvastatin has more advantages, and safe and reliable.